Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 3/20 | 0.51 |
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | MC3R | P41968 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648792 | 0.81 | CYP1A2 (0.47) | MC5RMC4RMC3RCYP1A2CYP2A6 | |
| SCHEMBL6008141 | 0.77 | MC5R (0.71) | MC5RMC4RMC3RCYP1A2CYP2A6 | |
| SCHEMBL3151696 | 0.76 | NPC1 (0.49) | KMT2AHDAC3 | |
| SCHEMBL27353 | 0.74 | CA2 (0.48) | IDO1CA12CA1CA2KMT2A | |
| SCHEMBL3159453 | 0.74 | CYP1A2 (0.52) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL272660 | 0.74 | CYP1A2 (0.54) | MC5RMC4RMC3RCYP1A2CYP2A6 | |
| SCHEMBL11445189 | 0.74 | MC5R (0.61) | MC5RMC4RMC3RCYP1A2CYP2A6 | |
| SCHEMBL9048936 | 0.74 | MC5R (0.56) | MC5RMC4RMC3RCYP1A2CYP2A6 | |
| SCHEMBL13607416 | 0.74 | MC5R (0.56) | MC5RMC4RMC3RCYP1A2CYP2A6 | |
| SCHEMBL30054430 | 0.74 | CYP1A2 (0.59) | MC5RMC4RMC3RCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797603-B1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | SOMALOGIC INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3335714-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | Quest Diagnostics Investments Incorporated (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2798085-B1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | QUEST DIAGNOSTICS INVEST INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9651556-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2683729-B1 | APTAMERS FOR CLOSTRIDIUM DIFFICILE DIAGNOSTICS | SOMALOGIC INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9316647-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | SOMALOGIC, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9081010-B2 | Aptamers for clostridium difficile diagnostics | SOMALOGIC, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150125867-A1 | Aptamers for Clostridium Difficile Diagnostics | SOMALOGIC OPERATING CO., INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150086996-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2015-03-26 | — | — | US | disclosed |
| US-8895241-B2 | Aptamers for clostridium difficile diagnostics | SOMALOGIC, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-6121282-A | 3-(CARBOXY, AMIDO, CYANO, OR HYDROXYAMINOCARBONYL)-6 OR 7-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1019378-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6040289-A | ACTIVE DRUG TREATING OBESITY | DR. KARL THOMAE GMBH (DE) | 2000-03-21 | — | — | US | disclosed |
| US-5962530-A | NEUROPEPTIDE Y ANTAGONIST | DR. KARL THOMAE GMBH (DE) | 1999-10-05 | — | — | US | disclosed |
| EP-0925063-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998000137-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000403-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |